Bearish Chart Formation for AC Immune SA (ACIU) After Forming H&S

June 16, 2018 - By Peter Erickson

The stock of AC Immune SA (ACIU) formed H&S with $9.02 target or 6.00 % below today’s $9.60 share price. The 5 months Head & Shoulders indicates high risk for the $551.05M company. It was reported on Jun, 16 by Faxor.com. If the $9.02 price target is reached, the company will be worth $33.06 million less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 4.58% or $0.42 during the last trading session, reaching $9.6. About 20,895 shares traded. AC Immune SA (NASDAQ:ACIU) has risen 16.72% since June 16, 2017 and is uptrending. It has outperformed by 4.15% the S&P500.

Analysts await AC Immune SA (NASDAQ:ACIU) to report earnings on August, 8. They expect $-0.23 earnings per share, down 4.55 % or $0.01 from last year’s $-0.22 per share. After $-0.20 actual earnings per share reported by AC Immune SA for the previous quarter, Wall Street now forecasts 15.00 % negative EPS growth.

More news for AC Immune SA (NASDAQ:ACIU) were recently published by: Benzinga.com, which released: “44 Biggest Movers From Yesterday” on June 05, 2018. Nasdaq.com‘s article titled: “Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics NV, BRF SA, and National Steel with …” and published on June 08, 2018 is yet another important article.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has market cap of $551.05 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases. It currently has negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

AC Immune SA (NASDAQ:ACIU) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: